MK0431 Safety and Efficacy in Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Pioglitazone Therapy
This phase 3 study aims to evaluate the safety and effectiveness of MK0431 in improving glycemic control, specifically by measuring changes in HbA1c levels after 24 weeks, in individuals with Type 2 Diabetes Mellitus who are currently not achieving adequate control with Pioglitazone therapy.
Comparator: Sitagliptin
+ Comparator: Pioglitazone
+ Metformin
Diabetes Mellitus+2
+ Diabetes Mellitus, Type 2
+ Endocrine System Diseases
Treatment Study
Summary
Study start date: June 1, 2004
Actual date on which the first participant was enrolled.The purpose of this study is to determine the safety and efficacy of an investigational drug in patients with type 2 diabetes mellitus.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.353 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Treatment Study
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.Over 18 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Criteria
Inclusion Criteria: * Patient has type 2 diabetes mellitus (T2DM) * Patient is 18 years of age (or older) * Patient is not pregnant or breast-feeding and does not plan to become pregnant for the duration of the study and poststudy follow-up period Exclusion Criteria: * Patient has a history of type 1 diabetes mellitus or a history of ketoacidosis * Patient required insulin within the prior 8 weeks * Patient is on a weight loss program and is not in the maintenance phase * Patient started on a weight loss medication (e.g., orlistat or sibutramine) within the prior 8 weeks * Patient is on or likely to require treatment with treatment with immunosuppressive agents (e.g., cyclosporin, methotrexate) * Patient has cirrhosis, active liver disease (other than fatty liver) or symptomatic gallbladder disease * Patient has chronic myopathy, or a progressive neurological or neuromuscular disorder (e.g., multiple sclerosis or polymyositis) * Patient has any of the following disorders within the past 6 months: Acute coronary syndrome (e.g., MI or unstable angina), Coronary artery intervention, Stroke or transient ischemic neurological disorder. * Patient has new or worsening signs or symptoms of coronary heart disease within the past 3 months * Patient has severe peripheral vascular disease * Patient has congestive heart failure * Patient is HIV positive * Patient has a clinically important hematological disorder (e.g., aplastic anemia, myeloproliferative or myelodysplastic syndromes, thrombocytopenia) * Patient has a history of neoplastic disease * Patient has a history of alcohol or drug abuse within the past 3 years * Patient has viral hepatitis (hepatitis B or C)
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.2 intervention groups are designated in this study
50% chance of being blinded to the placebo group
Treatment Groups
Group I
Active ComparatorGroup II
PlaceboStudy Objectives
Primary Objectives
Secondary Objectives